Cargando…

Apolipoprotein E4 carrier status plus circulating anti-NMDAR1 autoantibodies: association with schizoaffective disorder

Detalles Bibliográficos
Autores principales:	Hammer, C, Zerche, M, Schneider, A, Begemann, M, Nave, K-A, Ehrenreich, H
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2014
Materias:	Letter to the Editor
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4195337/ https://www.ncbi.nlm.nih.gov/pubmed/24888362 http://dx.doi.org/10.1038/mp.2014.52

Ejemplares similares

Cognitive Impact by Blood Circulating Anti-NMDAR1 Autoantibodies
por: Zhou, Xianjin
Publicado: (2021)

Uncoupling the widespread occurrence of anti-NMDAR1 autoantibodies from neuropsychiatric disease in a novel autoimmune model
por: Pan, Hong, et al.
Publicado: (2018)

Multiple inducers and novel roles of autoantibodies against the obligatory NMDAR subunit NR1: a translational study from chronic life stress to brain injury
por: Pan, Hong, et al.
Publicado: (2020)

Autoantibodies against NMDAR subunit NR1 disappear from blood upon anesthesia
por: Teller, Johannes, et al.
Publicado: (2022)

NMDAR1 autoantibodies amplify behavioral phenotypes of genetic white matter inflammation: a mild encephalitis model with neuropsychiatric relevance
por: Arinrad, Sahab, et al.
Publicado: (2021)

Chronic presence of blood circulating anti-NMDAR1 autoantibodies impairs cognitive function in mice
por: Yue, William, et al.
Publicado: (2021)

Allosteric Modulation of NMDARs Reverses Patients' Autoantibody Effects in Mice
por: Radosevic, Marija, et al.
Publicado: (2021)

NMDAR autoantibodies in psychiatric disease - An immunopsychiatric continuum and potential predisposition for disease pathogenesis
por: Hansen, Niels
Publicado: (2022)

Clinical, cognitive and neuroanatomical associations of serum NMDAR autoantibodies in people at clinical high risk for psychosis
por: Pollak, Thomas A., et al.
Publicado: (2020)

Schizoaffective Disorder and Concurrent Rhabdomyolysis
por: Varkey, Thomas, et al.
Publicado: (2021)

Carbamazepine and psychotherapy in the treatment of schizoaffective psychosis.
por: Cegalis, J. A., et al.
Publicado: (1985)

SCHIZOAFFECTIVE DISORDER : CONSISTENCY OF DIAGNOSIS
por: Shrivastava, Amresh, et al.
Publicado: (1999)

To live with a Schizoaffective disorder
por: Arndtzén, Mats, et al.
Publicado: (2020)

Valproate-induced hypothyroidism in schizoaffective disorder
por: Facucho-Oliveira, J., et al.
Publicado: (2022)

Spontaneous serum autoantibody fluctuations: To be or not to be
por: Ehrenreich, Hannelore, et al.
Publicado: (2020)

Dissociation of accumulated genetic risk and disease severity in patients with schizophrenia
por: Papiol, S, et al.
Publicado: (2011)

Neurophysiological Distinction between Schizophrenia and Schizoaffective Disorder
por: Mathalon, Daniel H., et al.
Publicado: (2010)

Circulating Autoantibodies Recognizing Immunodominant Epitopes From Human Apolipoprotein B Associate With Cardiometabolic Risk Factors, but Not With Atherosclerotic Disease
por: Marchini, Timoteo, et al.
Publicado: (2022)

Reducing the Diagnostic Heterogeneity of Schizoaffective Disorder
por: Seldin, Katherine, et al.
Publicado: (2017)

Cortical Alpha Activity in Schizoaffective Patients
por: Moeini, Mahdi, et al.
Publicado: (2017)

Schizoaffective disorder about 57 cases
por: Kammoun, I.
Publicado: (2021)

Autoantibodies to Apolipoprotein A-1 in Cardiovascular Diseases: Current Perspectives
por: Teixeira, P. C., et al.
Publicado: (2012)

Role of paliperidone extended-release in treatment of schizoaffective disorder
por: Canuso, Carla M, et al.
Publicado: (2010)

OTTO: a new strategy to extract mental disease-relevant combinations of GWAS hits from individuals
por: Ehrenreich, H, et al.
Publicado: (2018)

Prodromal headache in anti‐NMDAR encephalitis: An epiphenomenon of NMDAR autoimmunity
por: Tominaga, Naomi, et al.
Publicado: (2018)

Schizoaffective disorder induced by substance abuse: a case report
por: García Carpintero, A., et al.
Publicado: (2022)

Schizoaffective Disorder That Is Induced By Electrical Voltage That Is Treated with Risperidone
por: Fadhilah, Ihsan, et al.
Publicado: (2019)

Evidence of emerging BBB changes in mid‐age apolipoprotein E epsilon‐4 carriers
por: Alruwais, Nourah M., et al.
Publicado: (2022)

Alcohol Use Disorder and Schizophrenia or Schizoaffective Disorder
por: Archibald, Luke, et al.
Publicado: (2019)

Behavioural Changes in a Patient With Schizoaffective Disorder
por: Varughese, Anto
Publicado: (2022)

Autoantibodies against N-methyl-d-aspartate receptor 1 in health and disease
por: Ehrenreich, Hannelore
Publicado: (2018)

Schizoaffective disorder: Nosological controversies and absence of specific treatment guidelines
por: García, M. Valtueña, et al.
Publicado: (2021)

Clusterin accumulates in synapses in Alzheimer’s disease and is increased in apolipoprotein E4 carriers
por: Jackson, Rosemary J, et al.
Publicado: (2019)

Plasma Apolipoprotein E3 and Glucose Levels Are Associated in APOE ɛ3/ɛ4 Carriers
por: Edlund, Anna K., et al.
Publicado: (2021)

NMDAR-Activated PP1 Dephosphorylates GluN2B to Modulate NMDAR Synaptic Content
por: Chiu, Andrew M., et al.
Publicado: (2019)

Gait and balance in apolipoprotein Ɛ4 allele carriers in older adults and Parkinson’s disease
por: Morris, Rosie, et al.
Publicado: (2023)

Circulating immune complexes and autoantibodies in lung cancer.
por: Guy, K., et al.
Publicado: (1981)

Paliperidone Palmitate for Schizoaffective Disorder: A Review of the Clinical Evidence
por: Greenberg, William M., et al.
Publicado: (2015)

Cardiovascular Risk for Patients With and Without Schizophrenia, Schizoaffective Disorder, or Bipolar Disorder
por: Rossom, Rebecca C., et al.
Publicado: (2022)

Clinical factors affecting functioning in patients with schizophrenia or schizoaffective disorder
por: Neily, C., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_qub6i36qf3afivjhftmnloonm4